Key Takeaway
Important safety information about retatrutide and pregnancy, including recommended washout periods, fertility effects, and planning guidance for women of reproductive age.
Retatrutide shouldn't be used during pregnancy. Like all GLP-1 class medications, it should be discontinued at least 2 months before planned conception due to its long half-life and the potential risks that caloric restriction and metabolic disruption pose to fetal development. While retatrutide hasn't yet been approved by the FDA and specific reproductive safety data is limited, the precautionary principles established by semaglutide and tirzepatide apply directly.
Why GLP-1 Medications Are Contraindicated in Pregnancy
The concern with using GLP-1 receptor agonists during pregnancy is twofold. First, these medications work by reducing appetite and food intake, which creates a caloric deficit. During pregnancy, adequate caloric and nutritional intake is important for fetal growth and development. A medication that suppresses hunger and slows gastric emptying could lead to inadequate weight gain, nutritional deficiencies, and restricted fetal growth.
Second, animal studies with GLP-1 receptor agonists have shown reproductive toxicity. In studies with semaglutide, adverse developmental outcomes including embryonic death and structural abnormalities were observed in rats and rabbits at clinically relevant doses. While animal findings don't always translate directly to humans, they're serious enough to warrant a strong precautionary stance. No controlled studies have been conducted in pregnant women with any GLP-1 medication, and it would be unethical to design one.
Retatrutide adds complexity because it activates three receptors rather than one or two. The glucagon receptor and GIP receptor both play roles in metabolic regulation that could theoretically affect placental function, glucose delivery to the fetus, and maternal metabolic adaptation to pregnancy. Until these pathways are better understood in the context of human pregnancy, avoidance is the only responsible recommendation.
The Washout Period: Why Two Months Minimum
When clinicians recommend stopping retatrutide at least two months before attempting conception, this is based on pharmacokinetic principles. Retatrutide has a long half-life, meaning it remains active in the body for an extended period after the last injection. It takes approximately five half-lives for a drug to be effectively cleared from the system.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Placebo | 2 | ~2% weight loss |
| 4 mg | 17 | ~17% at 48 weeks |
| 8 mg | 22 | ~22% at 48 weeks |
| 12 mg | 24 | ~24% at 48 weeks |
Based on the dosing schedule used in clinical trials (once weekly), retatrutide's half-life appears to be in the range of six to seven days, similar to other long-acting GLP-1 agonists. Five half-lives would mean roughly 30 to 35 days for near-complete elimination. The two-month recommendation builds in a safety buffer beyond the minimum pharmacokinetic clearance time.
Semaglutide carries the same two-month washout recommendation in its prescribing information. Tirzepatide, with a slightly shorter half-life, has similar guidance. These aren't arbitrary timelines. They reflect a genuine effort to ensure no active drug remains in circulation when embryonic development begins, as the earliest weeks of pregnancy are when the fetus is most vulnerable to developmental disruption.
The "Ozempic Baby" Phenomenon
An unexpected development in the GLP-1 era has been the wave of unplanned pregnancies among women taking these medications. The phenomenon, widely discussed as "Ozempic babies," occurs for several well-understood physiological reasons.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Obesity is associated with hormonal imbalances that can impair fertility, including improved estrogen from adipose tissue, insulin resistance that disrupts ovulation, and conditions like polycystic ovary syndrome (PCOS). When women lose significant weight on GLP-1 medications, these hormonal disruptions often correct rapidly. Ovulation can resume in women who had been irregularly cycling or not ovulating at all, sometimes before they realize their fertility has changed.
Some women on oral contraceptives may experience reduced absorption due to the delayed gastric emptying caused by GLP-1 medications. If the pill isn't absorbed as efficiently, its contraceptive effectiveness may decrease. The FDA addressed this with tirzepatide by recommending that women on oral contraceptives switch to a non-oral method (such as an IUD, implant, or injection) or add a barrier method during treatment.
This same concern applies to retatrutide. Women of reproductive age who are taking retatrutide and not planning pregnancy should use reliable, non-oral contraception. An unplanned pregnancy on retatrutide would require immediate discontinuation of the medication and close obstetric monitoring.
Planning Pregnancy After Retatrutide Treatment
For women who are using retatrutide as part of a planned weight loss process before pregnancy, the sequence matters. Reaching a healthier weight before conceiving can meaningfully improve pregnancy outcomes, reducing risks of gestational diabetes, preeclampsia, cesarean delivery, and large-for-gestational-age infants. In this sense, retatrutide could be a valuable pre-conception tool if used with careful timing.
The recommended approach is to achieve your target weight or reach a stable plateau, then taper off retatrutide under medical supervision. Allow at least two full months after your last injection before attempting conception. During this washout period, focus on establishing sustainable eating and exercise habits that will support a healthy pregnancy without medication assistance.
Be aware that some weight regain is common after discontinuing GLP-1 medications. This is a normal physiological response as appetite-regulating hormones readjust. A modest amount of weight regain during the washout period and early pregnancy shouldn't cause alarm, but it's worth discussing with your physician so expectations are aligned.
Breastfeeding Considerations
There's no published data on whether retatrutide passes into human breast milk. For semaglutide and tirzepatide, animal studies have shown that the medications are present in the milk of lactating rats, though at low concentrations. Neither medication is recommended during breastfeeding due to the lack of human data.
The same precautionary principle applies to retatrutide. If you're breastfeeding and considering restarting weight loss medication, discuss the timing with your healthcare provider. Many women choose to complete breastfeeding before resuming GLP-1 therapy, while others may opt for earlier resumption if they're formula feeding.
What to Do If You Become Pregnant While on Retatrutide
If you discover you're pregnant while taking retatrutide, stop the medication immediately and contact your healthcare provider. Don't take your next scheduled dose. The long half-life means there will be a gradual tapering of the drug in your system even after the last injection, so some exposure in very early pregnancy is unavoidable in this scenario.
There's no need to panic. Inadvertent early pregnancy exposure to GLP-1 medications has occurred in clinical trials and post-marketing surveillance for semaglutide and tirzepatide. While the data is limited, there have been no clear signals of increased birth defects in these accidental exposure cases. Your obstetrician can arrange appropriate monitoring, which may include early ultrasounds and anatomy scans, to confirm normal fetal development.
Fertility and Retatrutide in Men
While most of the pregnancy-related concern focuses on women, men taking retatrutide should also be aware of potential reproductive considerations. Weight loss in obese men frequently improves testosterone levels, sperm quality, and sexual function. GLP-1 medications have been associated with improved reproductive hormone profiles in men with obesity. There's no current evidence that retatrutide or similar medications cause direct harm to sperm or male fertility, and in fact the weight loss itself may enhance reproductive capacity.
But men whose partners are trying to conceive should inform their doctors about retatrutide use so that any relevant considerations can be addressed.
The Core Message
Retatrutide and pregnancy don't mix. Stop the medication well before trying to conceive, use reliable contraception if pregnancy isn't desired, and work closely with your healthcare team to time your weight loss treatment and family planning goals appropriately. The metabolic benefits of reaching a healthier weight before pregnancy are substantial, but the medication itself must be out of your system before conception occurs.